From Cytokine Endotypes to Clinical Reality in Still’s Disease Save

Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. 

In OP0322, Guo et al. define cytokine-driven endotypes in adult-onset Still’s disease (AOSD) using integrated immune profiling across serum cytokines, immune cell phenotyping, and tissue-level validation. Three reproducible endotypes emerged: an IL-1β–dominant, a hyperinflammatory IL-6/IL-8/IFNγ-high, and a hypo-inflammatory state. These endotypes were not merely descriptive; they correlated with disease severity, immune activation patterns, and risk of macrophage activation syndrome (MAS). Importantly, the hyperinflammatory group demonstrated marked T-cell activation and hepatic immune infiltration, providing a mechanistic basis for more aggressive or combination cytokine targeting. This work moves the field toward precision immunophenotyping, offering a rational framework to guide biologic selection rather than empiric escalation.

Complementing these biologic insights, OP0194 provides real-world evidence on how such targeted strategies translate into clinical outcomes. Using the BiKeR registry, Horneff et al. demonstrate that EULAR/PReS treat-to-target goals—clinical inactive disease by 3 months and steroid-free remission by 6 months—are frequently achievable with IL-1 and IL-6 inhibition. Notably, canakinumab showed higher response rates compared with tocilizumab in several endpoints, reinforcing the clinical relevance of IL-1–dominant disease biology. Despite the limitations inherent to observational data, these findings affirm that cytokine-directed therapies can deliver meaningful, timely disease control in routine practice, aligning closely with the biologic endotypes defined above.

However, the abstract OP0334 further illustrates the complexity of immune modulation in Stills disease, where eosinophilic complications during IL-1/IL-6 inhibition may reflect a biologic-induced cytokine imbalance rather than true DRESS. The successful use of benralizumab  (IL-5 receptor) to target eosinophilic inflammation highlights an underrecognized axis of disease biology and management. Together, these findings emphasize the need to anticipate immune plasticity and pathway-specific toxicities as we refine precision approaches in Still’s disease.

Looking forward, emerging targets may further refine this paradigm. POS0331 identifies SLAMF7 as a novel mediator of IFNγ-driven neutrophil extracellular trap formation, linking innate immune activation to cytokine storm and MAS. Targeting SLAMF7 may be a novel mechanism in the future to interrupt this amplification loop and extend precision therapy beyond current cytokine blockade.